MAPT and Alzheimer disease: According to data from clinical studies and meta-analyses, levels of total tau and pTau in the CSF remain among the most reliable and sensitive biomarkers for both AD diagnosis and longitudinal monitoring of disease progression (Ibach et al., 2006; Welge et al., 2009; AlzBiomarker Database, 2018).